EUCTR2004-002425-52-IT进行中（未招募）不适用
A phase III, duble blinded, placebo controlled study of manteinance Pemetrexed plus Best Supportive Care Immediately following induction treatment for advance non-small cell lung cancer.
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- ELI LILLY
- 入组人数
- 660
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
A phase III, double-blind, placebo-controlled study to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in patients with idiopathic parkinson?s disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of a dopamine agonist and/or an anticholinergic - NDPATIENTS WITH IDIOPATHIC PARKINSON?S DISEASE WITH MOTOR FLUCTUATIONSMedDRA version: 9.1Level: LLTClassification code 10061536Term: Parkinson's diseaseEUCTR2006-005860-14-ITEWRON PHARMACEUTICALS600
进行中（未招募）
1 期
A phase III, double-blind, placebo-controlled study to determine the efficacy and safety of a low (50-100 mg/day) and high (150-200 mg/day) dose range of safinamide, as add-on therapy, in patients with early idiopathic parkinson’s disease treated with a stable dose of a single dopamine agonist.Early idiopathic Parkinson’s diseaseMedDRA version: 7.0Level: LLTClassification code 10013113EUCTR2004-000833-12-ESewron Pharmaceuticals S.p.A.
进行中（未招募）
不适用
A Phase III, double-blind, placebo-controlled study to determine the efficacy and safety of a low (50-100 mg/day) and high (150-200 mg/day) dose range of safinamide, as add-on therapy, in patients with early idiopathic Parkinson's Disease treated with a stable dose of a single dopamine agonistMedDRA version: 6.1Level: PTClassification code 10061536Parkinson's DiseaseEUCTR2004-000833-12-ITEWRON PHARMACEUTICALS
进行中（未招募）
1 期
A study of Xilonix? for Improving Survival in Colorectal CancerMetastatic colorectal cancerMedDRA version: 18.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864EUCTR2012-005287-10-ESXBiotech Germany GmbH600
进行中（未招募）
1 期
A study of Xilonix™ for patients with Colorectal CancerMetastatic colorectal cancerMedDRA version: 20.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000016864EUCTR2012-005287-10-GBXBiotech Germany GmbH600